cagrilintide 5mg+Semaglutide 5mg
cagrilintide 5mg+Semaglutide 5mg from the Nexus GLP-1 & Metabolic catalog, supplied for controlled in-vitro research workflows.
Ships from the US with tracking.
Catalog active: Catalog pricing is active. Live warehouse counts are not published.
Certificate pending — assay values withheld
Final assay values publish here once independent documentation is available. See the verification process.
For in-vitro research use only. Not for human consumption.
CagriSema combines Cagrilintide (an amylin receptor agonist) with Semaglutide (a GLP-1 receptor agonist) to enable research into dual-pathway metabolic signaling. This combination targets amylin receptors and GLP-1 receptors simultaneously, two complementary pathways involved in appetite regulation and metabolic homeostasis.
No sequence is listed in the current catalog record for this product.
- CAS
- N/A
- MW
- Cagrilintide: 4409.07 g/mol + Semaglutide: 4113.58 g/mol
- Sequence
- Not listed
- Half-life
- Not listed
- Formula
- Not listed
- Purity
- Certificate pending
- Form
- Lyophilized powder
- Class
- Dual Amylin/GLP-1 Combination
The dossier.
Compound Overview
CagriSema pairs Cagrilintide, an amylin receptor agonist, with Semaglutide, a GLP-1 receptor agonist, so researchers can examine dual-pathway metabolic signaling in controlled laboratory models. The blend is designed for simultaneous study of amylin receptors and GLP-1 receptors, two complementary signaling systems associated with appetite regulation and metabolic homeostasis research.
Research Background & Published Literature
The CagriSema combination has been evaluated in Phase 3 clinical trials focused on dual amylin/GLP-1 pathway activation. This research model provides a way to study how two distinct hormonal signaling systems may interact during metabolic regulation experiments.
Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:
Storage, Handling & Stability Guidelines
Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.
- Keep ambient-temperature exposure as brief as practical during handling to support compound integrity.
- Reseal vials promptly after each withdrawal to limit moisture exposure.
- Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
- For traceability, label all aliquots with compound name, concentration, reconstitution date, and operator initials.
Quality Assurance & Lab Verification
The Certificate of Analysis for this catalog item is pending. No provisional batch, assay, method, analyst, or release data is published in this product dossier. Check the Lab Verified archive for documentation status.
Shipping
Orders ship within the United States via USPS; international orders are not accepted. Laboratories should follow their validated SOP together with any handling fields published for the represented product or lot; no universal prepared-solution condition is inferred here.
Compound details.
- Molecular Weight
- Cagrilintide: 4409.07 g/mol + Semaglutide: 4113.58 g/mol
- Class
- Dual Amylin/GLP-1 Combination
Research context.
The CagriSema combination has been evaluated in Phase 3 clinical trials studying dual amylin/GLP-1 pathway activation. This represents a novel approach to studying how two distinct hormonal signaling systems interact in metabolic regulation.
Verification standard.
Certificate information is lot-specific. A finalized public record shows only the methods, fields, and results present for that named lot. A pending certificate state exposes no assay values and must not be interpreted as analytical verification. Review Nexus lab verification.
Certificate status.
Finalized independent certificate documentation is pending for this catalog record. Measurement details remain withheld until the certificate is available.
- Sequence
- Not listed
- Model preview
- Unavailable
Molecular model preview is unavailable for this catalog record.
The chemistry.
Fixed-dose combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist)
Technical specifications.
- Product Name: Cagrisema (2.5mg+2.5mg)
- Classification: Dual Amylin/GLP-1 Combination
- Structural Description: Fixed-dose combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist)
- Molecular Weight: Cagrilintide: 4409.07 g/mol + Semaglutide: 4113.58 g/mol
- Purity: ≥99% (verified by HPLC and Mass Spectrometry)
- Physical Form: Lyophilized (freeze-dried) powder
- Intended Use: In-vitro research use only — not for human consumption
Related research compounds
Comparable catalog records with published variants and certificate status.
- GLP-1 & MetabolicVerified batchSemaglutidePriceFrom $14.99Formats6 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 910463-68-2View product - GLP-1 & MetabolicVerified batchTirzepatidePriceFrom $28.99Formats10 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 2023788-19-2View product - GLP-1 & MetabolicVerified batchRetatrutidePriceFrom $45.99Formats8 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 2381089-83-2View product - GLP-1 & MetabolicVerified batchLiraglutidePriceFrom $113.99Formats3 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 204656-20-2View product - GLP-1 & MetabolicVerified batchMazdutidePriceFrom $94.99Formats2 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 2259884-03-0View product
cagrilintide 5mg+Semaglutide 5mg research FAQ.
What is cagrilintide 5mg+Semaglutide 5mg used for in research?
cagrilintide 5mg+Semaglutide 5mg is supplied for controlled in-vitro research workflows in the GLP-1 & Metabolic category. It is not labeled for human or veterinary use.
Does cagrilintide 5mg+Semaglutide 5mg have a finalized analytical record?
cagrilintide 5mg+Semaglutide 5mg is listed with certificate-pending status until a finalized lot-specific COA record is available.
Which cagrilintide 5mg+Semaglutide 5mg variants are published?
Published Nexus variants include 10mg.
Does cagrilintide 5mg+Semaglutide 5mg include a COA?
The current Nexus record marks cagrilintide 5mg+Semaglutide 5mg as certificate pending; finalized assay values are not shown until lot-specific documentation is available.